Strategies for Safety Reporting in Substance Abuse Trials

References

• Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. JAMA 2001; 285(4):437–443.
   PubMed Web of Science ®Google Scholar
• Czaja SJ, Schulz R, Belle SH, Burgio LD, Armstrong N, Gitlin LN, Coon DW, Martindale-Adams J, Klinger J, Stahl SM. Data and safety monitoring in social behavioral intervention trials: The REACH II experience. Clin Trials 2006; 3(2):107–118.
   PubMed Web of Science ®Google Scholar
• Papanikolaou PN, Churchill R, Wahlbeck K, Ioannidis JP. Safety reporting in randomized trials of mental health interventions. Am J Psychiatry 2004; 161(9):1692–1697.
   PubMed Web of Science ®Google Scholar
• Raisch DW, Troutman WG, Sather MR, Fudala PJ. Variability in the assessment of adverse events in a multicenter clinical trial. Clin Ther 2001; 23:2011–2020.
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Lau J. Improving safety reporting from clinical trials. Drug Saf 2002; 25(2):77–84.
   PubMed Web of Science ®Google Scholar
• O’Neill RT. A perspective on characterizing benefits and risks derived from clinical trials: Can we do more? Drug Inf J 2008; 42(3):235–245.
   Google Scholar
• Morse MA, Califf RM, Sugarman J. Monitoring and ensuring safety during clinical research. JAMA 2001; 285(9):1201–1205.
   PubMed Web of Science ®Google Scholar
• Califf RM, Morse MA, Wittes J, Goodman SN, Nelson DK, DeMets DL, Iafrate RP, Sugarman J. Toward protecting the safety of participants in clinical trials. Control Clin Trials 2003; 24(3):256–271.
   PubMedGoogle Scholar
• OHRP guidance on reviewing and reporting unanticipated problems involving risks to subjects or others and adverse events – January 15, 2007. Available at http://www.hhs.gov/ohrp/policy/AdvEvntGuid.htm. Last accessed on March 30, 2011.
   Google Scholar
• NIH guidance on reporting adverse events to institutional review boards for NIH-supported multicenter clinical trials – June 11, 1999. Available at http://grants1.nih.gov/grants/ guide/notice-files/not99-107.html. Last accessed on August 10, 2009.
   Google Scholar
• FDA guidance for clinical investigators, sponsors, and IRBs adverse event reporting to IRBs – improving human subject protection – January 2009. Available at http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ucm079753.pdf. Last accessed on August 17, 2009.
   Google Scholar
• NIH policy for data and safety monitoring – June 10, 1998. Available at http://grants.nih.gov/grants/guide/notice-files/not98-084.html. Last accessed on August 10, 2009.
   Google Scholar
• NIH Guide: Further guidance on a data and safety monitoring for phase I and phase II trials – June 5, 2000. Available at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-038.html. Last accessed on August 10, 2009.
   Google Scholar
• Petry NM, Roll JM, Rounsaville BJ, Ball SA, Stitzer M, Peirce JM, Blaine J, Kirby KC, McCarty D, Carroll KM. Serious adverse events in randomized psychosocial treatment studies: Safety or arbitrary edicts? J Consult Clin Psychol 2008; 76(6):1076–1082.
   PubMed Web of Science ®Google Scholar
• Killeen T, Hien D, Campbell A, Brown C, Hansen C, Jiang H, Kristman-Valente A, Neuenfeldt C, Rocz-de la Luz N, Sampson R, Suarez-Morales L, Wells E, Brigham G, Nunes E. Adverse events in an integrated trauma-focused intervention for women in community substance abuse treatment. J Subst Abuse Treat 2008; 35:304–311.
   PubMed Web of Science ®Google Scholar
• Tai B, Straus MM, Liu D, Sparenborg S, Jackson R, McCarty D. The first decade of the National Drug Abuse Treatment Clinical Trials Network: Bridging the gap between research and practice to improve drug abuse treatment. J Subst Abuse Treat 2010; 38:S4–S13.
   PubMed Web of Science ®Google Scholar
• Wells EA, Saxon AJ, Calsyn DA, Jackson TR, Donovan D. Study results from the Clinical Trials Network’s first 10 years: Where do they lead? J Subst Abuse Treat 2010; 38:S14–S30.
   PubMed Web of Science ®Google Scholar
• Horigian VE, Robbins MS, Dominguez R, Ucha J, Rosa CL. Principles for defining adverse events in behavioral intervention research: Lessons from a family-focused adolescent drug abuse trial. Clin Trials 2010; 7(1):58–68.
   PubMed Web of Science ®Google Scholar
• Rosa C, Campbell A, Kleppinger C, Sampson R, Tyson C, Mamay-Gentilin S. Quality assurance of research protocols conducted in the community: The National Institute on Drug Abuse Clinical Trial Network experience. Clin Trials 2009; 6:151–161.
   PubMed Web of Science ®Google Scholar
• Pan J, Nahm M, Wakim P, Cushing C, Poole L, Tai B, Pieper C. A centralized informatics infrastructure for the National Institute on Drug Abuse Clinical Trials Network. Clin Trials 2009; 6:67–75.
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use – June 10, 1996. ICH harmonised tripartite guideline. Guideline for Good Clinical Practice E6(R1). Available at http://www.ich.org/cache/compo/276-254-1.html. Last accessed on August 3, 2009.
   Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use – June 10, 1996. ICH harmonised tripartite guideline. Clinical Safety Data Management: Definitions and standards for expedited reporting E2A. Available at http://www.ich.org/cache/compo/475-272-1.html#E2A. Last accessed on August 3, 2009.
   Google Scholar
• Guidance for industry and investigators safety reporting requirements for INDs and BA/BE studies – September 2011. Available at http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM227351.pdf. Last accessed on March 20, 2011.
   Google Scholar
• Ling W, Hillhouse M, Domier C, Doraimani G, Hunter J, Thomas C, Jenkins J, Hasson A, Annon J, Saxon A, Selzer J, Boverman J, Bilangi R. Buprenorphine tapering schedule and illicit opioid use. Addiction 2009; 104:256–265.
   PubMed Web of Science ®Google Scholar
• Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, Brigham G, Harrer J, Reid M, Muir J, Buchan B, Orr D, Woody G, Krejci J, Ziedonis D; Buprenorphine Study Protocol Group. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings for the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005; 100:1090–1110.
   PubMed Web of Science ®Google Scholar
• Reid MS, Fallon B, Sonne S, Flammino F, Nunes EV, Jiang H, Kourniotis E, Lima J, Brady R, Burgess C, Arfken C, Pihlgren E, Giordano L, Starosta A, Robinson J, Rotrosen J. Smoking cessation treatment in community-based substance abuse rehabilitation programs. J Subst Abuse Treat. 2008; 35(1):68–77.
   PubMed Web of Science ®Google Scholar
• Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, Patkar A, Publicker M, McCain K, Potter JS, Forman R, Vetter V, McNicholas L, Blaine J, Lynch KG, Fudala P. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. JAMA 2008; 300(17):2003–2011. Erratum in: JAMA 2009;301(8):830.
   PubMed Web of Science ®Google Scholar